do-me/EUR-LEX huggingface dataset:
Information relating to the entry into force of the Agreement between the European Union and the Democratic Republic of Timor Leste on the short-stay visa waiver
Date: 2022-04-13
Institutions: Council of the European Union
Subjects: EU visa policy, East Timor, Schengen Agreement, agreement (EU), external border of the EU, foreign national








L_2022115EN.01004201.xml










13.4.2022   


EN


Official Journal of the European Union


L 115/42







Information relating to the entry into force of the Agreement between the European Union and the Democratic Republic of Timor Leste on the short-stay visa waiver

The Agreement between the European Union and the Democratic Republic of Timor Leste on the short-stay visa waiver will enter into force on 1 May 2022, the procedure provided for in Article 8(1) of the Agreement having been completed on 23 March 2022.
Case T-202/22: Action brought on 13 April 2022 — TA Towers v EUIPO — Wobben Properties (Building materials)
Date: 2022-04-13
Institutions: General Court
Subjects: building materials, designs and models








C_2022222EN.01003702.xml










7.6.2022   


EN


Official Journal of the European Union


C 222/37






Action brought on 13 April 2022 — TA Towers v EUIPO — Wobben Properties (Building materials)
(Case T-202/22)
(2022/C 222/61)
Language in which the application was lodged: English

Parties


Applicant: TA Towers ApS (Odense, Denmark) (represented by: L. Andersen, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Wobben Properties GmbH (Aurich, Germany)

Details of the proceedings before EUIPO


Proprietor of the design at issue: Applicant before the General Court

Design at issue: Community design No 6 352 332-0001 (Building materials)

Procedure before EUIPO: Cancellation proceedings

Contested decision: Decision of the Third Board of Appeal of EUIPO of 11 February 2022 in Case R 2493/2020-3

Form of order sought

The applicant claims that the Court should:






—


annul the contested decision;










—


annul the decision of the Cancellation Division of 20 November 2020 in Case ICD 108 309;










—


order EUIPO and the invalidity applicant to pay the costs of the proceedings before the Cancellation Division, the Board of Appeal and the General Court.





Pleas in law







—


Infringement of Article 6 of Council Regulation (EC) No 6/2002;










—


Infringement of Article 8 of Council Regulation (EC) No 6/2002;










—


Infringement of Article 62 of Council Regulation (EC) No 6/2002.
Case C-268/22: Request for a preliminary ruling from the Nederlandstalige rechtbank van eerste aanleg Brussel (Belgium) lodged on 13 April 2022 — VITOL SA v Belgische Staat
Date: 2022-04-13
Institutions: Court of Justice
Subjects: Argentina, Indonesia, anti-dumping duty, biofuel, import (EU), originating product








C_2022318EN.01002101.xml










22.8.2022   


EN


Official Journal of the European Union


C 318/21






Request for a preliminary ruling from the Nederlandstalige rechtbank van eerste aanleg Brussel (Belgium) lodged on 13 April 2022 — VITOL SA v Belgische Staat
(Case C-268/22)
(2022/C 318/30)
Language of the case: Dutch

Referring court

Nederlandstalige rechtbank van eerste aanleg Brussel

Parties to the main proceedings


Applicant: VITOL SA

Defendant: Belgische Staat

Question referred

Is Implementing Regulation No 1194/2013, (1) as amended by Regulation 2017/1578, (2) contrary to the basic regulation No 1225/2009, (3) inter alia because:






—


it has not been demonstrated that the conditions were met for disregarding, in the context of calculating the normal value of the like product, the costs associated with the production and sale of that product, as reflected in the records of the Argentinian exporting producers examined, in accordance with the rule laid down in Article 2(5) of the basic regulation,










—


the effects of the imports were erroneously assessed cumulatively in accordance with Article 3(4) of the basic regulation and it was thus not adequately demonstrated that dumped imports had caused injury within the meaning of the basic regulation, as referred to in Article 3(6) and (7) of that regulation,










—


and there was thus no question of dumping and no anti-dumping duty could be imposed as referred to in Article 1 of the basic regulation?






(1)  Council Implementing Regulation (EU) No 1194/2013 of 19 November 2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia (OJ 2013 L 315, p. 2).

(2)  Commission Implementing Regulation (EU) 2017/1578 of 18 September 2017 amending Council Implementing Regulation (EU) No 1194/2013 imposing a definitive anti-dumping duty and collecting definitively the provisional duty imposed on imports of biodiesel originating in Argentina and Indonesia (OJ 2017 L 239, p. 9).

(3)  Council Regulation (EC) No 1225/2009 of 30 November 2009 on protection against dumped imports from countries not members of the European Community (OJ 2009 L 343, p. 51).
Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (OJ L 396, 30.12.2006, p. 1.)) (Text with EEA relevance) 2022/C 160/11
Date: 2022-04-13
Institutions: Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, European Commission
Subjects: chemical compound, chemical product, health control, health risk, market approval, marketing standard, medical device, pharmaceutical industry








C_2022160EN.01010501.xml










13.4.2022   


EN


Official Journal of the European Union


C 160/105






Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)


(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)
(2022/C 160/11)

Decision granting an authorisation













Reference of the decision (2)



Date of decision


Substance name


Holder of the authorisation


Authorisation number


Authorised use


Date of expiry of review period


Reasons for the decision




C(2022) 2174


8 April 2022


4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
(4-tert-OPnEO)
EC No: -, CAS No:-


BioMérieux SA, Chemin de l’Orme, 69280 Marcy-l’Etoile, France


REACH/22/22/0


Industrial use of 4-tert OPnEO for its non-ionic detergent properties consisting in the filling of 4-tert-OpnEO-containing solutions into specific single-use ampoules to be included in clinical and industrial in vitro testing applications as part of the BioFire and BioFire Next Gen FA products


4 January 2025


In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.






(1)  OJ L 396, 30.12.2006, p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu).
Case T-695/21: Order of the General Court of 13 April 2022 — Alauzun and Others v Commission (Action for annulment and for failure to act — Public health — Medicinal products for human use — Conditional marketing authorisation for mRNA-technology vaccines — Lack of carcinogenicity and genotoxicity studies — Time limit for bringing proceedings — Delay — No invitation to act — Position taken — No interest in bringing proceedings — Lack of direct concern — Lack of individual concern — Inadmissibility — Request for the Court to issue directions — Lack of jurisdiction)
Date: 2022-04-13
Institutions: General Court
Subjects: carcinogenic substance, clinical trial, coronavirus disease, drug surveillance, epidemic, injunction, limitation of legal proceedings, market approval, toxic substance, vaccine








C_2022284EN.01004102.xml










25.7.2022   


EN


Official Journal of the European Union


C 284/41






Order of the General Court of 13 April 2022 — Alauzun and Others v Commission
(Case T-695/21) (1)

(Action for annulment and for failure to act - Public health - Medicinal products for human use - Conditional marketing authorisation for mRNA-technology vaccines - Lack of carcinogenicity and genotoxicity studies - Time limit for bringing proceedings - Delay - No invitation to act - Position taken - No interest in bringing proceedings - Lack of direct concern - Lack of individual concern - Inadmissibility - Request for the Court to issue directions - Lack of jurisdiction)
(2022/C 284/56)
Language of the case: French

Parties


Applicants: Virginie Alauzun (Saint Cannat, France) and the 773 other applicants whose names are listed in the annex to the order (represented by: F. Di Vizio, lawyer)

Defendant: European Commission (represented by: G. Gattinara and L. Haasbeek, acting as Agents)

Re:

By their action under Articles 263, 265 and 266 TFEU, the applicants ask the General Court (i) to declare that the European Commission unlawfully failed to include carcinogenicity and genotoxicity testing in the preclinical phase during the procedure granting the conditional marketing authorisation to mRNA-technology vaccines, (ii) to order the Commission to include such testing in past and future EMA procedures and (iii) to request the EMA to communicate certain information relating to that testing.

Operative part of the order







1.


The action is dismissed as inadmissible.










2.


There is no longer any need to adjudicate on the application for leave to intervene submitted by Moderna Biotech Spain SL.










3.


Ms Virginie Alauzun and the other applicants whose names are included in the annex shall bear their own costs and pay those incurred by the European Commission.










4.


Moderna Biotech Spain shall bear its own costs relating to the application to intervene.






(1)  OJ C 2, 3.1.2022
Euro exchange rates (Source: reference exchange rate published by the ECB.) 12 April 2022 2022/C 160/08
Date: 2022-04-13
Institutions: European Commission
Subjects: euro, exchange rate, money








C_2022160EN.01002601.xml










13.4.2022   


EN


Official Journal of the European Union


C 160/26






Euro exchange rates (1)

12 April 2022
(2022/C 160/08)

1 euro =











 


Currency


Exchange rate




USD


US dollar


1,0861 




JPY


Japanese yen


136,29 




DKK


Danish krone


7,4379 




GBP


Pound sterling


0,83455 




SEK


Swedish krona


10,3320 




CHF


Swiss franc


1,0131 




ISK


Iceland króna


139,60 




NOK


Norwegian krone


9,5395 




BGN


Bulgarian lev


1,9558 




CZK


Czech koruna


24,450 




HUF


Hungarian forint


377,78 




PLN


Polish zloty


4,6552 




RON


Romanian leu


4,9417 




TRY


Turkish lira


15,9548 




AUD


Australian dollar


1,4599 




CAD


Canadian dollar


1,3724 




HKD


Hong Kong dollar


8,5112 




NZD


New Zealand dollar


1,5874 




SGD


Singapore dollar


1,4803 




KRW


South Korean won


1 335,49 




ZAR


South African rand


15,8490 




CNY


Chinese yuan renminbi


6,9199 




HRK


Croatian kuna


7,5513 




IDR


Indonesian rupiah


15 609,66 




MYR


Malaysian ringgit


4,5972 




PHP


Philippine peso


56,574 




RUB


Russian rouble


 




THB


Thai baht


36,531 




BRL


Brazilian real


5,0944 




MXN


Mexican peso


21,5616 




INR


Indian rupee


82,7285 






(1)  Source: reference exchange rate published by the ECB.
Case T-199/22: Action brought on 13 April 2022 — Perfetti Van Melle v EUIPO (Representation of a cylindrical container with a wavy outline)
Date: 2022-04-13
Institutions: General Court
Subjects: EU trade mark, cosmetic product, dental medicine, dietary product, pharmaceutical product, polishing and scouring preparations, registered trade mark, toiletries, trade-mark law








C_2022222EN.01003601.xml










7.6.2022   


EN


Official Journal of the European Union


C 222/36






Action brought on 13 April 2022 — Perfetti Van Melle v EUIPO (Representation of a cylindrical container with a wavy outline)
(Case T-199/22)
(2022/C 222/59)
Language of the case: Italian

Parties


Applicant: Perfetti Van Melle SpA (Lainate, Italy) (represented by: P. Testa and C. Pappalardo, lawyers)

Defendant: European Union Intellectual Property Office (EUIPO)

Details of the proceedings before EUIPO


Trade mark at issue: Application for EU figurative mark (Representation of a cylindrical container with a wavy outline) — Application for registration No 18 355 641

Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 10 February 2022 in Case R 1530/2021-5

Form of order sought

The applicant claims that the Court should:






—


annul the contested decision;










—


order EUIPO to pay the costs.





Plea in law







—


Infringement of Article 7(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.
Case T-20/22: Order of the General Court of 13 April 2022 — NW v Commission
Date: 2022-04-13
Institutions: General Court
Subjects: European official, claim, debt, interest, remuneration of work, right to justice, staff regulations (EU), tax relief








C_2022276EN.01002503.xml










18.7.2022   


EN


Official Journal of the European Union


C 276/25






Order of the General Court of 13 April 2022 — NW v Commission
(Case T-20/22) (1)

(2022/C 276/37)
Language of the case: French
The President of the Fourth Chamber has ordered that the case be removed from the register.


(1)  OJ C 95, 28.2.2022.
Case T-201/22: Action brought on 13 April 2022 — TA Towers v EUIPO — Wobben Properties (Building materials)
Date: 2022-04-13
Institutions: General Court
Subjects: building materials, designs and models








C_2022222EN.01003701.xml










7.6.2022   


EN


Official Journal of the European Union


C 222/37






Action brought on 13 April 2022 — TA Towers v EUIPO — Wobben Properties (Building materials)
(Case T-201/22)
(2022/C 222/60)
Language in which the application was lodged: English

Parties


Applicant: TA Towers ApS (Odense, Denmark) (represented by: L. Andersen, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Wobben Properties GmbH (Aurich, Germany)

Details of the proceedings before EUIPO


Proprietor of the design at issue: Applicant before the General Court

Design at issue: Community design No 6 352 332-0002 (Building materials)

Procedure before EUIPO: Cancellation proceedings

Contested decision: Decision of the Third Board of Appeal of EUIPO of 11 February 2022 in Case R 2491/2020-3

Form of order sought

The applicant claims that the Court should:






—


annul the contested decision;










—


annul the decision of the Cancellation Division of 20 November 2020 in Case ICD 108 310;










—


order EUIPO and the invalidity applicant to pay the costs of the proceedings before the Cancellation Division, the Board of Appeal and the General Court.





Pleas in law







—


Infringement of Article 6(1)(b) of Council Regulation (EC) No 6/2002;










—


Infringement of Article 8 of Council Regulation (EC) No 6/2002;










—


Infringement of Article 62 of Council Regulation (EC) No 6/2002.
Case T-192/22: Action brought on 13 April 2022 — Polynt v ECHA
Date: 2022-04-13
Institutions: General Court
Subjects: acid, chemical industry, disclosure of information, principle of proportionality, trade information








C_2022222EN.01003301.xml










7.6.2022   


EN


Official Journal of the European Union


C 222/33






Action brought on 13 April 2022 — Polynt v ECHA
(Case T-192/22)
(2022/C 222/55)
Language of the case: English

Parties


Applicant: Polynt SpA (Scanzorosciate, Italy) (represented by: C. Mereu and S. Abdel-Qader, lawyers)

Defendant: European Chemicals Agency

Form of order sought

The applicants claim that the Court should:






—


declare the application admissible and well-founded;










—


annul the decision of the European Chemicals Agency, sent by letter of 4 February 2022 (FUP- DEV-01-21200655590-58-0000-CCH-1-2_FTR_NOTIF), informing of a failure to respond to a dossier evaluation decision;










—


declare — or order ECHA to adopt a new measure declaring — that the Applicant is released from the obligation to provide any information to ECHA following the cease of production and consequent unavailability of the substance concerned due to force majeure; and










—


order ECHA to pay all costs of these proceedings.





Pleas in law and main arguments

In support of the action, the applicant relies on four pleas in law.






1.


First plea in law, alleging that the Defendant breached the principle of force majeure when it held that the cease of manufacture of the substance 1,3-dioxo-2-benzofuran-5- carboxylic acid with nonan-1-ol (EC Number 941-303-6) (hereinafter ‘the substances’) after the adoption of the final compliance check decision for reasons of force majeure does not relieve the Appellant from the obligation to provide the information requested in the initial compliance check decision on the substances.










2.


Second plea in law, alleging that the Defendant breached Article 50(2) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (1) (‘REACH Regulation’).










3.


Third plea in law, alleging that the Defendant breached Articles 5 and 6 of the REACH Regulation.










4.


Fourth plea in law, alleging that the Defendant infringed the principle of proportionality.






(1)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ 2006 L 396, p. 1).
Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (OJ L 396, 30.12.2006, p. 1.)) (Text with EEA relevance) 2022/C 160/10
Date: 2022-04-13
Institutions: Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, European Commission
Subjects: chemical compound, chemical process, chemical product, health control, health risk, market approval, marketing standard, medical device, medical diagnosis, pharmaceutical industry








C_2022160EN.01010401.xml










13.4.2022   


EN


Official Journal of the European Union


C 160/104






Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)


(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)
(2022/C 160/10)

Decision granting an authorisation













Reference of the decision (2)



Date of decision


Substance name


Holder of the authorisation


Authorisation number


Authorised use


Date of expiry of review period


Reasons for the decision




C(2022) 2163


8 April 2022


4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
(4-tert-OPnEO)
EC No: -, CAS No:-


DiaSorin S.p.A., via Crescentino Snc, 13040 Saluggia (VC), Italy


REACH/22/20/0


Industrial use, as non-ionic surfactant, employed in the purification of antigens in in vitro diagnostics tests for infectious diseases, auto immunity markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology


4 January 2033


In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies






(1)  OJ L 396, 30.12.2006, p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu).